SecBot SecBot
SECBOTREPLAY Home › Report › ACAD

ACAD · Acadia Pharmaceuticals appointed Jonathan M

ACADIA PHARMACEUTICALS INC · 8-K filed Mar 5, 2026 at 06:03 ET

At the news

NEUTRALIMPACT 3/10

8-K filed Mar 5, 2026 at 06:03 ET

Acadia Pharmaceuticals appointed Jonathan M. Poole to its board of directors and the Audit Committee, effective March 3, 2026. Poole will receive cash retainers totaling $62,500 annually (prorated) and initial equity awards with a target fair value of $200,000, plus a prorated annual grant valued at $95,300.

  • Jonathan M. Poole appointed to the Board of Directors and Audit Committee effective March 3, 2026
  • Poole is a non-employee director serving as a Class II director with term expiring at the 2027 Annual Meeting
  • He will receive annual cash retainers of $50,000 (Board) and $12,500 (Audit Committee), prorated and payable per policy
  • Received initial equity grant with target fair value of $200,000, split equally between stock options and RSUs, vesting over three years

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access